• 1
    El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87107.
  • 2
    Okuda K, Ohtsuki T, Obata H et al. Natural history of HCC and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 91828.
  • 3
    Lau H, Fan ST, Ng IO, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998; 83: 230211.
  • 4
    Herrero JI, Sangro B, Quiroga J et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001; 7: 6316.
  • 5
    Llad L, Virgili J, Figueras J et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 507.
  • 6
    CLIP Group. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31: 8405.
  • 7
    Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89: 226673.
  • 8
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 32938.
  • 9
    Farinati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? Eur J Cancer Prev 2001; 10: 1115.
  • 10
    Puisieux A, Ozturk M. p53 and hepatocellular carcinoma. Pathol Biol 1997; 45: 86470.
  • 11
    Itoh H, Shiro T, Seki T et al. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med 2000; 6: 137142.
  • 12
    Ito Y, Matsuura N, Sakon M et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 747751.
  • 13
    Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385392.
  • 14
    Ito Y, Matsuura N, Sakon M et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 74751.
  • 15
    Tang ZY, Qin LX, Wang XM et al. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J 1998; 111: 3138.
  • 16
    Ramsey WH, Wu GY. Hepatocellular carcinoma: update on diagnosis and treatment. Dig Dis 1995; 13: 8191.
  • 17
    Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 6939.
  • 18
    Livraghi T. Role of percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Dig Dis 2001; 19: 292300.
  • 19
    Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 157883.
  • 20
    CLIP Group (Cancer of the Liver Italian Program). Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 1998; 352: 1720.
  • 21
    Villa E, Ferretti I, Grottola A et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001; 84: 8815.
  • 22
    Lygidakis NJ, Tygat GNJ. Hepatobiliary and pancreatic malignancies. Diagnosis, medical and surgical management. Ed Micarelli 1990; 3: 267.
  • 23
    Endo K, Terada D. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationship with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 2000; 32: 7884.
  • 24
    Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Saisho H. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology 1998; 45: 121420.
  • 25
    Molmenti EP, Klintmann GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002; 8: 73648.
  • 26
    Llovet JM, Fuster J, Bruix J. Prognosis of hepatocellular carcinoma. Hepatogastroenterology 2002; 49: 711.
  • 27
    Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 42130.
  • 28
    Nzeako UC, Goodamn ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and non-cirrhotic livers. A clinico-pathologic study of 804 North American patients. Am J Clin Pathol 1996; 105: 6575.
  • 29
    Lauwers GY, Terris B, Balis UJ et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002; 26: 2534.
  • 30
    Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S. The significance of p53 mutation as an indicator of biologic behaviour of recurrent hepatocellular carcinomas. Surg Today 1999; 29: 849855.
  • 31
    Sheen IS, Jeng KS, Wu Jy. Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol 2003; 9: 12027.